...Thank you, Deborah, and those attending today's earnings call. Dr. Shai Gozani, NeuroMetrix's President and CEO, is participating in this Q1 2021 review. NeuroMetrix is a leader in proprietary noninvasive medical devices for the diagnosis and treatment of pain and neurological disorders. We design and deploy a recurring revenue business model in all of our products. These commercial products include the neurodiagnostic technologies of DPNCheck and ADVANCE, plus our primary chronic pain technology, Quell. Our Q1 2021 earnings release demonstrated continued progress toward profitability combined with modest net cash usage. Among the relevant details from the Q1 results, Q1 revenue was $2.2 million. This represented 19% sequential growth from the fourth quarter of 2020 and approximately flat revenue with Q1 of 2020. Our sense is, there continues to be some delay, albeit diminishing, and our customer base returning to its pre-pandemic diagnostic testing levels. DPNCheck was the lead revenue...
